Status:

UNKNOWN

Inflammatory Bowel Disease (IBD) and Covid-19 Infection

Lead Sponsor:

University Hospital, Strasbourg, France

Conditions:

Inflammatory Bowel Disease

Eligibility:

All Genders

18+ years

Brief Summary

Most of the inflammatory bowel disease (IBD: Crohn's disease and ulcerative colitis) in a tertiary expert Centre are on immunosuppressive and/or biological therapy. Theoretically, these treatments may...

Eligibility Criteria

Inclusion

  • Patient over the age of 18 years
  • IBD patients (Crohn's disease, ulcerative colitis, indeterminate colitis)
  • Patient agreeing to participate in the study

Exclusion

  • Patient unable to understand the study protocol or to answer simple anamnestic questions due to language barrier
  • Patient under guardianship or trusteeship
  • Patient under safeguard of justice

Key Trial Info

Start Date :

July 7 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

January 7 2021

Estimated Enrollment :

700 Patients enrolled

Trial Details

Trial ID

NCT04492267

Start Date

July 7 2020

End Date

January 7 2021

Last Update

July 30 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Service Hépato-Gastroentérologie et Assistance Nutritive Hôpitaux Univesitaires de Strasbourg

Strasbourg, France, 67091

Inflammatory Bowel Disease (IBD) and Covid-19 Infection | DecenTrialz